Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016', provides in depth analysis on Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2)
- The report reviews Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Overview 7
Therapeutics Development 8
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Stage of Development 8
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Therapy Area 9
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Indication 10
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Companies 14
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Products under Development by Universities/Institutes 16
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 24
Array BioPharma Inc. 24
Bristol-Myers Squibb Company 25
Genentech, Inc. 26
Nimbus Therapeutics, LLC 27
Portola Pharmaceuticals, Inc. 28
Sareum Holdings Plc 29
Takeda Pharmaceutical Company Limited 30
Theravance Biopharma, Inc. 31
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Drug Profiles 32
ARRY-111 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
cerdulatinib - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SAR-20347 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
SART-1 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
SART-29 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SART-33 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit TYK2 for Immunology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Inhibit TYK2 for Psoriasis and IBD - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit TYK2 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit Tyk2 for Inflammation and Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TD-1473 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Discontinued Products 47
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Featured News & Press Releases 48
Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 48
Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 49
Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 50
Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 50
Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 51
Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 52
Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 53
Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs 54
Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 55
Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK 55
May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib 56
May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting 57
Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme 58
Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting 59
Oct 01, 2014: Sareum Holdings Promising Step in Psoriasis Drug Development 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Assessment by Monotherapy/Combination Products, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 23
Pipeline by Array BioPharma Inc., H1 2016 24
Pipeline by Bristol-Myers Squibb Company, H1 2016 25
Pipeline by Genentech, Inc., H1 2016 26
Pipeline by Nimbus Therapeutics, LLC, H1 2016 27
Pipeline by Portola Pharmaceuticals, Inc., H1 2016 28
Pipeline by Sareum Holdings Plc, H1 2016 29
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 30
Pipeline by Theravance Biopharma, Inc., H1 2016 31
Discontinued Products, H1 2016 47